TODAY -

Latest advancements in TB science in spotlight

Bobby Ramakant *



Important game-changing scientific advancements in preventing and treating TB (TB or tuberculosis, is among the deadliest of infectious diseases globally), were in spotlight at the recently concluded International Conference on Retroviruses and other Opportunistic Infections (CROI 2022).

If we look at the pace at which new better tools to prevent, diagnose, or treat TB have come in the past decades, it is a deeply painful realisation because despite scientific advancements, the pace of TB research and investment that has gone into it, is way off mark.

We still use more than a century old diagnostics, drugs that are too toxic, therapies that are too long and may cause post-treatment disabilities, treatment outcomes that can never be accepted as 'gold standard', and half-heartedly made measly investment promises, continue to hold us back in the fight to #endTB. That is why listening to new TB science updates at CROI 2022 was in particular a ray of hope for me.

Latest TB science updates included those regarding two most historically neglected areas: treatment for drug-susceptible TB (common TB when bacteria is not resistant to medicines) and latent TB (TB prevention). “Advancing TB science is vital because it is TB that is robbing us of gains made in advancing HIV treatment science and rollout. TB is the most common opportunistic infections among people living with HIV and a major cause of untimely deaths among them.

In 2020, there were 214,000 deaths from TB among people living with HIV. Even one TB death is a death too many. When TB is preventable, when TB is curable, then how can even one TB death occur in any sane and just society? We have to walk the talk on oft-chanted #EverylifeMatters,” said Shobha Shukla, founder of CNS (Citizen News Service) who was on the panel “CROI 2022: Global Advocates Offer Insights and Directions on the Science and Next Steps Needed.”

Harry Tembo, Zambia Community Advisory Platform, Zambia; Katie Willingham, The Well Project, United States; Richard Jefferys, Treatment Action Group, United States; Shobha Shukla, CNS, India; and Simon Collins, i-Base and EATG, United Kingdom were among the panelists and session was moderated by HIV prevention research stalwart-advocate Jim Pickett.

Latest advancements in drug-susceptible TB

Study 31/A5349 found that a new treatment regimen (combination of medicines) for treating drug-susceptible TB of the lungs in adults and adolescents, can effectively and safely cure TB in 4 months, instead of 6 months (when treated with current standard regimens). This new regimen used in the study had a combination of 4 medicines: Isoniazid, Rifapentine, Moxifloxacin, and Pyrazinamide.

The study concluded that this new regimen of 4 months was non-inferior to the current standard regimen of 6 months. In fact the overall efficacy results for HIV positive sub-group were higher at 85% as compared to 78% cure rate for participants who were living with HIV in the standard of care regimen group. This regimen is the first successful short-course treatment regimen for drug-susceptible TB disease in almost 40 years. WHO has endorsed this regimen for use [CDC guidance is forthcoming], said Shobha Shukla.

New research for treating TB in children

Another study called SHINE which was done in Africa and India, compared outcomes using a treatment regimen for 4 and 6 months respectively to treat smear-negative and non-severe forms of TB of the lungs in children (HIV positive and negative both included). Isoniazid, Rifampicin, Ethambutol and Pyrazinamide were the medicines used in the regimen. Study concluded that the 4-months duration therapy was non-inferior to standard 6-months duration therapy. Only 3% unfavourable outcomes and few toxicity related side-effects were reported in both groups (4 and 6 months duration treatment groups).

New research for better MDR-TB preventive treatments

Many ongoing studies are evaluating 6-months multi drug-resistant TB (MDR-TB) preventive therapies for close contacts of MDR-TB patients. TB CHAMP study is examining Levofloxacin medicine to be used as part of MDR-TB preventive therapy in children below 5 years of age, who are close contacts of adult MDR-TB patients.

PHOENix (Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients) study is comparing Delamanid with Isoniazid for preventing MDR-TB in children, adolescents and adults who are close contacts of persons with MDR-TB.

V-QUIN study in Vietnam is examining the efficacy of Levofloxacin for treating latent MDR-TB in all household contacts of patients with bacteriologically-confirmed Rifampicin-resistant TB.

Research ongoing for long-acting injectables for treating TB

Long-acting injectable possible formulations of TB drugs could have several potential benefits, like improved adherence, greater acceptability, and better integration of TB preventive therapy into other treatment programmes, like those for HIV, maternal and child health, said Shobha Shukla.

CROI also shared information on new TB drugs, including long acting injectables, that are in various stages of development: TBAJ-876, a next generation diarylquinoline, is in phase-1 of multiple ascending dose (MAD) study. It has shown improved safety, pharmacokinetics and superior potency. Sutezolid and Delpazolid are new oxazolidinones in phase 2b/2c studies.

DprE1 inhibitors (a novel class of anti-TB agents) are also being developed. OPC-167832, in combination with Bedaquiline and Delamanid, is being evaluated for safety and efficacy of a 4-months regimen for drug-sensitive TB. GSK3036656, a novel translational inhibitor, has been found to be safe and well tolerated after single and multiple doses in its First-Time-in-Human Study for shorter treatment regimen.

Existing TB drug Bedaquiline could be a potential suitable candidate for long acting injectable. One single dose of long acting formulation of Bedaquiline was found to maintain drug and metabolite concentration for up to 3 months in mice. Modelling results expect that this would also be observed in the clinic. New diarylquinolines (like TBAJ-876) may be good candidates for long-acting TB preventive therapy.

Treatment of MDR-TB

Until recently, the standard of care MDR-TB treatment regimen was 18-24 months long and gave a cure of around 50% with highly toxic drugs and painful daily injections given for a minimum of the first 6-months of treatment.

TB PRACTECAL study led by MSF is evaluating a 6 months all oral regimens containing Bedaquiline and Pretomanid in combination with Linezolid, Moxifloxacin and Clofazimine. The study design has 4 groups: one group gets the WHO standard of care regimen; second group gets a regimen of Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin; third group gets a regimen of Bedaquiline, Pretomanid, Linezolid, and Clofazimine; and fourth group gets a regimen of Bedaquiline, Pretomanid, and Linezolid.

As of now, a regimen of Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin, with a tapered dose of Linezolid, has been found to be non-inferior (safe and efficacious) to the standard of care (9-24 months) treatment of rifampicin-resistant TB of the lungs. Outcomes of other regimens are expected to be reported soon.

Nix-TB and ZeNix studies have already found an all-oral short-course 6-months treatment regimen of Bedaquiline, Pretomanid and Linezolid, for highly drug-resistant TB patients (MDR-TB, XDR-TB, pre-XDR-TB) to be safe and efficacious with a treatment success rate of 90% even in HIV infected MDR-TB patients. In ZeNix study, Linezolid dosage was reduced from 1200 mg to 600 mg to decrease toxicity, and duration was reduced from six months to two months, without affecting treatment success rate.

Preventing TB cannot be on the backseat

"Globally Directly Observed Treatment Shortcourse (DOTS) has been in use since 1980s. In India it was launched in 1997 as part of the Revised National TB Control Programme (RNTCP) which is now known as National TB Elimination Programme or NTEP. This current standard DOTS therapy (6 months long regimen) for TB treatment is a lifesaving therapy for those who do not have drug-resistance and get cured, but we cannot forget that this is not the gold standard by any means - this therapy remains burdensome to patients and their care providers, and toxic for many. We need better, more effective, less toxic, shorter treatment for drug-sensitive TB too," said Shobha Shukla.

She added: "For MDR-TB and extensively drug-resistant TB (XDR-TB) treatments, governments need to implement scientifically proven, shorter, and patient-centric treatment options with reduced number of drugs and minimal side effects."

"Why is there an unacceptably-long delay in rolling out best of science outcomes to those people who are most in need?" asks firebrand feminist and health rights activist Shobha Shukla.

Shobha said that testing and treating active TB disease is not enough if we want to end TB worldwide, unless we diagnose those with latent TB infection (especially those who are at greater risk) and provide them TB preventive treatments so that their risk of getting active TB disease is as low as possible. Not only we have not addressed latent TB infection adequately - historically - but we have even rolled existing programmes unsatisfactorily.

For example, in India use of Isoniazid preventive therapy (IPT) to reduce risk of active TB disease in children and people living with HIV with latent TB was offered even before rollout of lifesaving antiretroviral therapy (ART) began in 2004. But the ground reality of IPT rollout after almost two decades, is simply unacceptable.


* Bobby Ramakant wrote this article for e-pao.net
The writer is a World Health Organization (WHO) Director General’s WNTD Awardee 2008 and serves on the CNS (Citizen News Service) editorial.
Follow him on Twitter @BobbyRamakant
This article was webcasted on May 26 2022.



* Comments posted by users in this discussion thread and other parts of this site are opinions of the individuals posting them (whose user ID is displayed alongside) and not the views of e-pao.net. We strongly recommend that users exercise responsibility, sensitivity and caution over language while writing your opinions which will be seen and read by other users. Please read a complete Guideline on using comments on this website.




LATEST IN E-PAO.NET
  • Colonial Knowledge Production in NE #8
  • Violence in Manipur 2023-2025 : Timeline
  • The fight for survival in Manipur
  • A call for unity from displaced voices
  • COVID-19: Update 08 July 2025 : Manipur
  • Dogs Are Staying on the Ground :: Poem
  • Football Tournament at Heinoukhongnembi
  • Condemns Kuki Inpi's Directive
  • Installation Ceremony of Lions Club, Imphal
  • All that can go wrong has gone wrong
  • Manipur peaceful from Delhi's perspective
  • Bashanta Ras @Govindaji #2 : Gallery
  • Hypocrisy & the betrayal of sovereignty
  • Healing with Art for children concluded
  • Manipur : Champions 24th Junior Natl Wushu
  • Path to Becoming a Leader Who Inspires
  • Van Mahotsav 2025, festival of life
  • The Flavours of Life :: Poem
  • Assault on sensibilities of the media
  • Revival of MPP after years of bitter disputes
  • Ougri Lirol :: Part 2 : Ooba Video
  • Jianreilung, Chingamba, Masounii : eMing
  • How Jessami conservation of Nongin
  • Shija Hospitals turns 40
  • COVID-19: Update 06 July 2025 : Manipur
  • The Indomitable Young Souls :: Poem
  • Growing network of drug dealers in country
  • Politics of SoO pact since 2008
  • No takers for disturbance-free education
  • 31st Governor Cup Polo Tournament : Gallery
  • PM welcome to Manipur: Feel the reality
  • Kainkhol wins best Social Message Film Award
  • Distortion of facts: Manipur sports movement
  • Govt services reach Manipur's tribal villages
  • 134th Durand Cup Trophies Flag Off
  • COVID-19: Update 05 July 2025 : Manipur
  • How to take care of oily skin in monsoon
  • First-Ever Tripura Esports Championship
  • Konung Kang Chingba #1 : Gallery
  • Manipur Iskcon's 25th Ratha Yatra 2025
  • Native Threshing machine made for farmers
  • COVID-19: Update 04 July 2025 : Manipur
  • Riso Ejang: Youth-led Transformation
  • Include males too in addressing HPV
  • Whispers from the past :: Poem
  • LPU opens permanent outreach centre
  • Raj Bhavan moving on the right track
  • Speculations over PM Modi's visit to state
  • Colonial Knowledge Production in NE #7
  • Make Yourself Visible to Opportunity
  • Orange bowl: tradition with ecological wisdom
  • 10 ways to keep a kitchen garden disease free
  • Between PR, military mandates & AFSPA
  • Allocation fund for MLALAD Fund during PR
  • Denounces Killing of KNA Deputy C-in-C
  • COVID-19: Update 03 July 2025 : Manipur
  • Cases of fake Aadhaar cards
  • Sincere dealing must for stricter Aadhaar
  • Archaeology: Culture of Manipur : Booklet
  • Wanna be a singer? Get Botox
  • A Central institute in Manipur
  • Nagging in the name of love
  • COVID-19: Update 02 July 2025 : Manipur
  • 'Benefits' of Indira's Emergency
  • Social Stigma :: Poem
  • Inking a peace pact: Why, how: SoO quagmire
  • Van Mahotsav under shadow of declining forest
  • 11th Th Kishan Memorial Lecture : Gallery
  • Manipur crisis & the Left media's blind spot
  • COVID-19: Update 01 July 2025 : Manipur
  • Bombom RK : Musclemania Universe NYC
  • The Grief :: Poem
  • Music Concert & Quiz (MCQ) 2.0
  • SoO agreement unlikely to be scrapped
  • Regulating use of plastic carry bags
  • Mera Houchongba @Kangla #4 : Gallery
  • International Day of Yoga @JNMDA : Gallery
  • BD Behring: The inimitable Gentleman I knew
  • Violence in the name of patriotism : Misguided
  • Daily oral vs long-acting injectable for HIV
  • COVID-19: Update 30 June 2025 : Manipur
  • Smile :: Poem
  • Why was President's Rule imposed ?
  • BJP under pressure to forge unity
  • Kang @Leikai in Imphal : Gallery
  • July Calendar for Year 2025 : Tools
  • COVID-19 : A recurring crisis in Manipur
  • DC Kaith and Forestry in Manipur : Book
  • COVID-19: Update 29 June 2025 : Manipur
  • Longing for Peace :: Poem
  • Black badge, slogan protest by peeved scribes
  • Present the true picture before Delhi
  • Pung-Cholom @ Polo Tournament : Gallery
  • Life: A Journey Through Thought & Being
  • Khongjai Hills & Kuki claim to indigeneity
  • Master Time by Managing Information
  • COVID-19: Update 28 June 2025 : Manipur
  • Pride & patriotism in CCpur's army families
  • The Power of Poppy - 87 :: Poem
  • World Decarbonisation Day: green environment
  • Welcome Home - Nganthoi #2 : Gallery
  • Loss of two precious lives from Manipur
  • Balancing civil liberties with public safety
  • COVID-19: Update 27 June 2025 : Manipur
  • Gender equality & human rights are indivisible
  • Stay hydrated this summer season
  • Silent Half of the Sun :: Poem
  • Connecting the dots in the wishlist
  • Assembly record tampering claims by ex-CM
  • The immortal legacy of Pukhramba Kajao
  • International Day against Drug Abuse 2025
  • COVID-19: Update 26 June 2025 : Manipur
  • Black pottery from Ukhrul - tribal heritage
  • Program on "Mission-Drug Free Campus"
  • Play makes a better world
  • Urgent Appeal to the Honourable MLAs
  • Tribal Empowerment Campaign at CCpur
  • Talk doing the round: PM to come
  • 'Emergency' relief for under-fire BJP
  • Golden Jubilee Art Fair @Imphal : Gallery
  • Declaration: Meetei People Convention, Delhi
  • A Flower Among the Rocks :: Review
  • Book Donation Campaign
  • Improved road connectivity boosts livelihoods
  • To Have Great Dreams :: Poem
  • COVID-19: Update 25 June 2025 : Manipur
  • Regret vs Sorry: Technical & moral insight
  • Cocktail of inept Govt, selfish people
  • State trailing others in cleanliness
  • Colonial Knowledge in NE India #6
  • UHI effect & rising temperatures in Manipur
  • Frequent road blockades cripple economy
  • COVID-19: Update 24 June 2025 : Manipur
  • Unite Health with Community health services
  • NSU, Imphal, tops IIRF Ranking 2025
  • Endless conflict :: Poem
  • Pak nobel pish prize for Trump
  • May 3, 2023 - June 24, 2025: Failure of Delhi
  • Hotter days, sudden rainfall no more a rarity
  • "The Great June Uprising" #2 : Gallery
  • How to Build a Career, Lead with Purpose
  • 2nd Foundation Day- Karnataka Meitei Assn
  • COVID-19: Update 23 June 2025 : Manipur
  • NSCN-IM Amnesty threatens to isolate it
  • Sunset :: Poem
  • Intl Yoga Day for a healthier environment
  • Of clogged drains and plastics
  • Poor roads testify Govt indifference
  • Welcome Home - Nganthoi #1 : Gallery
  • The Silent Erosion of Manipuri Language
  • Design health services around people
  • Serene Hills Host Inspiring Int'l Yoga Day
  • COVID-19: Update 22 June 2025 : Manipur
  • Chopper services between Senapati & Imphal
  • High Court Judges interacted with convicts
  • Redyeing the Fabric :: Poem
  • Differences yet to be resolved stand
  • Border fencing rage as solution eludes
  • Radio E-pao: 14 new songs updated
  • Climate Adaptive Agroforestry
  • Manipur overlooked demographic shifts
  • Young designers shine on Fashion Stage
  • COVID-19: Update 21 June 2025 : Manipur
  • International Day of Yoga at Lamphelpat
  • International Day of Yoga at JNMDA
  • The Power of Poppy - 86 :: Poem
  • Keishampat Lairembi Haraoba #1 : Gallery
  • Crisis in Manipur's Contemporary Education
  • Best 8 Performances in Manipuri Cinema
  • Identity: Caught between China & India ?
  • COVID-19: Update 20 June 2025 : Manipur
  • To The Father Who Listens :: Poem
  • How does net suspension affect youths ?
  • Targeting farmers to cripple state's economy
  • The virus is back and spreading
  • Who is afraid of Manipur ?
  • A threatened lily growing at Shirui Hills
  • World Environment Day in Manipur : Gallery
  • Ambubachi Mela at Maa Kamakhya
  • COVID-19: Update 19 June 2025 : Manipur
  • Dolls made from repurposed vegetable refuse
  • Condemns Attack on Farmer & Killing
  • Abhorrent politics of SoO
  • Police arrogance on harmless drivers
  • "The Great June Uprising" #1 : Gallery
  • UK Meetei diaspora run for Myanmar : Gallery
  • Thang-Ta Day @Khuman Lampak #3 : Gallery
  • 50 years of Pebet #2 : Gallery
  • Indo-Naga Talks (From 2012) :: Timeline
  • Protest @Checkon -AT arrest [Jun 9] : Gallery
  • Protests - AT arrest [Jun 8 night] : Gallery
  • Aftermath of flooding @ Khurai #1 : Gallery
  • /li>
  • Flooding at JNIMS Hospital #2 : Gallery
  • North East NSS Festival @ MU : Gallery
  • Trump's tariff legacy & its global echo
  • Flooding Imphal East [31 May] #3 : Gallery
  • Flooding Imphal East [31 May] #2 : Gallery
  • Flooding Imphal East [31 May] #1 : Gallery
  • S Nirupama @Miss Universe : Gallery
  • Protesters to Raj Bhavan [May 25]: Gallery
  • Human Chain @Airport road [May 26]: Gallery
  • Miss Shirui Pageant Contestant: Gallery
  • 48 hrs Bandh: protest security forces: Gallery
  • Protest Rally: Journalist harassment: Gallery
  • HSLC 2025: Full Result (Check Roll No)
  • HSLC 2025: Important Info & Grading System
  • HSLC 2025 : Compartmental candidates
  • HSLC 2025 : Comparative Statement
  • HSLC 2025 : Statistical Abstract
  • HSLC 2025 : District Pass Percentage
  • HSLC 2025 : Govt School Pass %
  • HSLC 2025 : Aided School Pass %
  • HSLC 2025 : Private School Pass %
  • People's Convention on 3rd May #2 : Gallery
  • Featured Front Page Photo 2025 #2: Gallery
  • Riya Khwairakpam : HSE Science Topper
  • Keisham Hannah : HSE Arts Topper
  • Warepam Lidia : HSE Commerce Topper
  • HSE 2025 Result : Science Full Result
  • HSE 2025 Result : Arts Full Result
  • HSE 2025 Result : Commerce Full Result
  • HSE 2025 Information / Abbreviation
  • HSE 2025 Topper : Science
  • HSE 2025 Topper : Arts
  • HSE 2025 Topper : Commerce
  • HSE 2025 : Pass Percentage
  • HSE 2025 : Result Abstract
  • HSE 2025 : Candidates with Highest Marks
  • President's Rule in Manipur : 1967 - 2025
  • Downloadable Manipuri Calendar :: 2025